Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
LETROZOLE
SANIS HEALTH INC
L02BG04
LETROZOLE
2.5MG
TABLET
LETROZOLE 2.5MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0132937001; AHFS:
APPROVED
2020-09-02
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LETROZOLE letrozole tablets Tablets, 2.5 mg, for oral use USP Aromatase inhibitor Sanis Health Inc. 1 President's Choice Circle Brampton, Ontario L6Y 5S5 Submission Control Number: 278227 Date of Initial Authorization: SEP 02, 2020 Date of Revision: SEP 01, 2023 LETROZOLE _(letrozole)_ Tablets Page 2 of 58 RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, MUSCULOSKELETAL TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ........................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1. INDICATIONS .............................................................................................................. 4 1.1. Paediatrics ......................................................................................................................... 4 1.2. Geriatrics ........................................................................................................................... 4 2. CONTRAINDICATIONS ................................................................................................. 4 3. SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4. DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1. Dosing Considerations ...................................................................................................... 5 4.2. Recommended Dose and Dosage Adjustment ................................................................. 5 4.4. Administration .................................................................................................................. 6 4.5. Missed Dose ...................................................................................................................... 6 5. OVERDOSAGE ........................................................................... Belgenin tamamını okuyun